Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISM8207 in Advanced Solid Tumors and Relapsed/Refractory B-cell Lymphoma
NCT06445517Phase 1Recruiting
- Sponsor
- Insilico Medicine
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ISM8207 in solid tumor and B cell lymphoma (2 arms), sponsored by Insilico Medicine. Primary endpoints: Dose-limiting toxicity at 31 days, Adverse Events at 2 years and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
ISM8207
03
Conditions
solid tumorB cell lymphoma
Beyond the preview
Go deeper on NCT06445517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445517.